8-K

============================================================================

                                UNITED STATES
                     SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C. 20549

                     ----------------------------------



                                  FORM 8-K

                               CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF
                     THE SECURITIES EXCHANGE ACT OF 1934

                        Commission File Number 1-9601

       Date of Report (date of earliest event reported): April 1, 2003


                         K-V PHARMACEUTICAL COMPANY
           (Exact name of registrant as specified in its charter)


              DELAWARE                                 43-0618919
   (State or other jurisdiction of        (I.R.S. Employer Identification No.)
   incorporation or organization)

        2503 SOUTH HANLEY ROAD
         ST. LOUIS, MISSOURI                              63144
 (Address of principal executive offices)               (Zip Code)


                               (314) 645-6600
            (Registrant's telephone number, including area code)


============================================================================





ITEM 7.           FINANCIAL STATEMENTS AND EXHIBITS

         (a)      Financial statements. Not applicable.
                  --------------------

         (b)      Pro forma financial information. Not applicable.
                  -------------------------------

         (c)      Exhibits. See Exhibit Index.
                  --------

ITEM 9.           REGULATION FD DISCLOSURE

         On April 1, 2003, K-V Pharmaceutical Company's Ther-Rx Corporation
subsidiary acquired from Schwarz Pharma the Niferex(R) product line for
approximately $14.3 million. In addition, on April 2, 2003 the Ther-Rx
Corporation acquired from Germany's ALTANA Pharma AG the Chromagen(R) and
StrongStart(R) product lines comprising six products. See Press Releases
attached as Exhibits 99.1 and 99.2.

                                 *    *    *






                                 SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

Dated: April 3, 2003

                                  K-V PHARMACEUTICAL COMPANY



                                  By: /s/ Gerald R. Mitchell
                                      -------------------------------
                                      Gerald R. Mitchell
                                      Vice President, Treasurer and
                                      Chief Financial Officer



EXHIBIT INDEX

Exhibit No.       Description
- -----------       -----------

99.1              Press Release, dated April 1, 2003, issued by
                  K-V Pharmaceutical Company.

99.2              Press Release, dated April 2, 2003, issued by
                  K-V Pharmaceutical Company.

EX-99.1

                                                                EXHIBIT 99.1

KV PHARMACEUTICAL COMPANY ACQUIRES NIFEREX(R) PRODUCT LINE FROM SCHWARZ PHARMA


4/01/03

Third Acquisition for KV's Ther-Rx Branded Marketing Unit Expands

Company Into Hematinic Category

ST. LOUIS, April 1 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company
(NYSE: KVa/KVb) announced today that it has concluded an agreement with
Schwarz Pharma to acquire the Niferex(R) product line for its Ther-Rx
Corporation branded marketing division. The Niferex(R) product line
includes: Niferex(R) Tablets, Niferex(R) 150 Capsules and Niferex(R) 150
Forte. The transaction, valued at approximately $14.3 million and including
applicable intellectual property for each of the products, will position KV
to build a leading position in this oral hematinic market.

The acquisition adds approximately $5 million in annual net sales and will
expand Ther-Rx's current therapeutic areas of women's health and
cardiovascular products into the hematinic therapeutic category, which
includes drugs used in the treatment of anemias. According to Verispan, the
oral hematinic market in the U.S. is approximately $95 million (12 months
ended February 2003).

Similar to its strategy with other acquired products, formulation
enhancements are anticipated to be made by KV scientists to the acquired
product line. These products will be promoted through physician samples and
direct mail programs to high prescribers and are expected to be immediately
accretive to KV's branded product subsidiary, Ther-Rx Corporation.

Marc S. Hermelin, Vice Chairman of the Board and Chief Executive Officer
stated, "This acquisition will provide a unique and attractive opportunity
to establish not only a beachhead, but an immediate leadership position in
the hematinic category. Like we have with the PreCare(R) Caplet and other
products, our strategy in hematinics is to apply KV technologies to the
Niferex(R) line to further distinguish the brand as a leader in its category
and to build the franchise. Ther-Rx has been built on a dual strategy of
product acquisition and internal development and has demonstrated success at
both. We look forward to continuing to build upon this approach with these
products. Our plan is to move effectively and expeditiously to build a new
franchise with an aim of being number one."

The foremost example of KV's acquisition model is the PreCare(R) Caplet, a
product with approximately $4 million of annual revenues and declining at a
rate of approximately 20% when the company acquired it in 1999. After
reformulation and the addition of internally developed line extensions by
the Company's scientific group, Ther-Rx Corporation has increased the sales
of this line to over $20 million annually, and by doing so, KV has built a
prenatal nutritional franchise around the PreCare(R) brand and achieved a
500%-plus improvement in sales for the product line in just over three
years.

About KV Pharmaceutical

Company KV Pharmaceutical Company is a fully integrated specialty
pharmaceutical company that develops, acquires, manufactures and markets
controlled release and tastemasked pharmaceutical products using proprietary
drug delivery and tastemasking technologies. The company markets its
technology-distinguished products through ETHEX Corporation, a national
leader in pharmaceuticals that compete with branded products, and Ther-Rx
Corporation, its emerging branded drug subsidiary. KV has






consistently ranked as one of America's fastest growing small companies,
most recently by Forbes in its October 2002 issue.

For further information about KV Pharmaceutical Company, please visit the
Company's corporate website at www.kvpharmaceutical.com.

Safe Harbor

The information in this release may contain various forward-looking
statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include
assumptions, concerning KV's operations, future results and prospects. Such
statements may be identified by the use of words like "plans," "expect,"
"aim," "believe," " projects," "anticipate," "intend," "estimate," "will,"
"should," "could" and other expressions that indicate future events and
trends. All statements that address expectations or projections about the
future, including without limitation, statements about the Company's
strategy for growth, product development, market position, expenditures and
financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are
subject to risk and uncertainties. In connection with the "safe harbor"
provisions, KV provides the following cautionary statements identifying
important economic, political and technology factors which, among others,
could cause the actual results or events to differ materially from those set
forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in
the current and future business environment, including interest rates and
capital and consumer spending; (2) the difficulty of predicting FDA
approvals; (3) acceptance and demand for new pharmaceutical products; (4)
the impact of competitive products and pricing; (5) new product development
and launch; (6) reliance on key strategic alliances; (7) the availability of
raw materials; (8) the regulatory environment; (9) fluctuations in operating
results; (10) the difficulty of predicting the pattern of inventory
movements by the Company's customers; (11) the impact of competitive
response to the Company's efforts to leverage its brand power with product
innovation, promotional programs, and new advertising; and, (12) the risks
detailed from time to time in the Company's filings with the Securities and
Exchange Commission.

This discussion of uncertainties is by no means exhaustive, but is designed
to highlight important factors that may impact the Company's outlook.

/CONTACT: Catherine M. Biffignani, Vice President, Investor Relations
+1-314-645-6600, for KV Pharmaceutical Company/

                                     2

EX-99.2

                                                                EXHIBIT 99.2


KV PHARMACEUTICAL COMPANY ACQUIRES TWO PRODUCT LINES FROM ALTANA INC.


4/02/03

Second Hematinic Acquisition

Company Also Strengthens Prenatal Nutritional Leadership

ST. LOUIS, Mo., April 2 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company
( NYSE: KVa/KVb) announced today that it has concluded an agreement with the
U.S. subsidiary of Germany's ALTANA Pharma AG to acquire the Chromagen(R)
and StrongStart(R) product lines comprising six products for its Ther-Rx
Corporation Branded Marketing Division. The transaction is valued at
approximately $27 million. The transaction, which includes the applicable
intellectual property for each of the products, combined with the recently
announced acquisition of the Niferex(R) line from Schwarz Pharma gives the
company a significant position in the hematinic therapeutic category while
at the same time enhancing its presence in the branded prenatal vitamin
segment.

The acquisition brings in products with current aggregate annual net sales
of approximately $11 million in the U.S. The acquired products include the
hematinic products Chromagen(R), Chromagen(R) FA and Chromagen(R) Forte, as
well as the prenatal brand Chromagen(R) OB. The transaction also includes
the prenatal vitamin products StrongStart(R) Caplets and StrongStart(R)
Chewables.


Three of these products will augment Ther-Rx's expansion into the hematinic
therapeutic category, which includes drugs used in the treatment of anemias.
According to Verispan, the oral hematinic market in the U.S. is
approximately $ 95 million (12 months ended February 2003). The three
remaining products will further enhance Ther-Rx Corporation's position in
the prescription prenatal nutritional marketplace. Ther-Rx is currently the
leading branded prescription prenatal nutritional provider in the U.S. with
its Continuum of Care prescription products for women now capturing over 35%
of the branded market. Enhancements are anticipated to be made by KV
Pharmaceutical's drug delivery research scientists to certain of the
acquired products.

All of these products are expected to be immediately accretive to Ther-Rx
Corporation.

Marc S. Hermelin, Vice Chairman of the Board and Chief Executive Officer
stated, "These six products represent two exciting new growth platforms for
our Ther-Rx branded products division. The vitamin products enhance our
already strong position in women's nutritionals, while the three hematinic
products, together with our announced acquisition of the Niferex(R) line
from Schwarz Pharma, immediately establish Ther-Rx as a leader in the oral
hematinic market. The hematinic category has attributes that should be
familiar to followers of KV: a profitable, but relatively overlooked segment
in which today's advanced drug delivery technologies have been slow to be
applied. Our parallel expertise in both technology development and marketing
should enable us to reinvigorate the oral hematinic category through the
building of a distinguished brand franchise, following the same model that
has established the Company's PreCare(R) Continuum of Care prenatal product
line as "America's Number One Branded Prenatal line" with 35% market share."

The purchase price was structured with a $13 million payment at closing with
two promissory notes of $7 million payable one year and two years following
closing.






About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical
company that develops, acquires, manufactures and markets controlled release
and tastemasked pharmaceutical products using proprietary drug delivery and
tastemasking technologies. The company markets its technology-distinguished
products through ETHEX Corporation, a national leader in pharmaceuticals
that compete with branded products, and Ther-Rx Corporation, its emerging
branded drug subsidiary. KV has consistently ranked as one of America's
fastest growing small companies, most recently by Forbes in its October 2002
issue.

For further information about KV Pharmaceutical Company, please visit the
Company's corporate website at www.kvpharmaceutical.com

Safe Harbor

The information in this release may contain various forward-looking
statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include
assumptions, concerning KV's operations, future results and prospects. Such
statements may be identified by the use of words like "plans," "expect,"
"aim," "believe," " projects," "anticipate," "intend," "estimate," "will,"
"should," "could" and other expressions that indicate future events and
trends. All statements that address expectations or projections about the
future, including without limitation, statements about the Company's
strategy for growth, product development, market position, expenditures and
financial results, are forward- looking statements.

All forward-looking statements are based on current expectations and are
subject to risk and uncertainties. In connection with the "safe harbor"
provisions, KV provides the following cautionary statements identifying
important economic, political and technology factors which, among others,
could cause the actual results or events to differ materially from those set
forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in
the current and future business environment, including interest rates and
capital and consumer spending; (2) the difficulty of predicting FDA
approvals; (3) acceptance and demand for new pharmaceutical products; (4)
the impact of competitive products and pricing; (5) new product development
and launch; (6) reliance on key strategic alliances; (7) the availability of
raw materials; (8) the regulatory environment; (9) fluctuations in operating
results; (10) the difficulty of predicting the pattern of inventory
movements by the Company's customers; (11) the impact of competitive
response to the Company's efforts to leverage its brand power with product
innovation, promotional programs, and new advertising; and, (12) the risks
detailed from time to time in the Company's filings with the Securities and
Exchange Commission.

This discussion of uncertainties is by no means exhaustive, but is designed
to highlight important factors that may impact the Company's outlook.

/CONTACT: Catherine M. Biffignani, Vice President, Investor Relations of KV
Pharmaceutical Company, +1-314-645-6600 /

                                      2